IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v12y2021i1d10.1038_s41467-021-26870-z.html
   My bibliography  Save this article

Spatial and temporal intratumour heterogeneity has potential consequences for single biopsy-based neuroblastoma treatment decisions

Author

Listed:
  • Karin Schmelz

    (Charité—Universitätsmedizin Berlin
    The German Cancer Consortium (DKTK), Partner Site Berlin
    The German Cancer Research Center (DKFZ))

  • Joern Toedling

    (Charité—Universitätsmedizin Berlin
    The German Cancer Consortium (DKTK), Partner Site Berlin
    The German Cancer Research Center (DKFZ))

  • Matt Huska

    (Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC))

  • Maja C. Cwikla

    (Charité—Universitätsmedizin Berlin
    Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC))

  • Louisa-Marie Kruetzfeldt

    (Charité—Universitätsmedizin Berlin)

  • Jutta Proba

    (Charité—Universitätsmedizin Berlin)

  • Peter F. Ambros

    (St. Anna Kinderkrebsforschung)

  • Inge M. Ambros

    (St. Anna Kinderkrebsforschung)

  • Sengül Boral

    (Charité—Universitätsmedizin Berlin)

  • Marco Lodrini

    (Charité—Universitätsmedizin Berlin
    The German Cancer Consortium (DKTK), Partner Site Berlin
    The German Cancer Research Center (DKFZ))

  • Celine Y. Chen

    (Charité—Universitätsmedizin Berlin
    Experimental and Clinical Research Center (ECRC) of the Charité and Max Delbrück Center for Molecular Medicine in the Helmholtz Association)

  • Martin Burkert

    (Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC))

  • Dennis Guergen

    (Experimental Pharmacology and Oncology Berlin-Buch GmbH (EPO))

  • Annabell Szymansky

    (Charité—Universitätsmedizin Berlin)

  • Kathy Astrahantseff

    (Charité—Universitätsmedizin Berlin)

  • Annette Kuenkele

    (Charité—Universitätsmedizin Berlin
    The German Cancer Consortium (DKTK), Partner Site Berlin
    The German Cancer Research Center (DKFZ)
    Berlin Institute of Health (BIH))

  • Kerstin Haase

    (Charité—Universitätsmedizin Berlin
    The German Cancer Consortium (DKTK), Partner Site Berlin
    The German Cancer Research Center (DKFZ)
    Berlin Institute of Health (BIH))

  • Matthias Fischer

    (Department of Experimental Pediatric Oncology, Medical Faculty, University Children’s Hospital of Cologne
    University of Cologne)

  • Hedwig E. Deubzer

    (Charité—Universitätsmedizin Berlin
    The German Cancer Consortium (DKTK), Partner Site Berlin
    The German Cancer Research Center (DKFZ)
    Experimental and Clinical Research Center (ECRC) of the Charité and Max Delbrück Center for Molecular Medicine in the Helmholtz Association)

  • Falk Hertwig

    (Charité—Universitätsmedizin Berlin
    The German Cancer Consortium (DKTK), Partner Site Berlin
    The German Cancer Research Center (DKFZ))

  • Patrick Hundsdoerfer

    (Charité—Universitätsmedizin Berlin
    Helios Klinikum Berlin-Buch)

  • Anton G. Henssen

    (Charité—Universitätsmedizin Berlin
    The German Cancer Consortium (DKTK), Partner Site Berlin
    The German Cancer Research Center (DKFZ)
    Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC))

  • Roland F. Schwarz

    (Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC)
    BIFOLD—Berlin Institute for the Foundations of Learning and Data)

  • Johannes H. Schulte

    (Charité—Universitätsmedizin Berlin
    The German Cancer Consortium (DKTK), Partner Site Berlin
    The German Cancer Research Center (DKFZ)
    Berlin Institute of Health (BIH))

  • Angelika Eggert

    (Charité—Universitätsmedizin Berlin
    The German Cancer Consortium (DKTK), Partner Site Berlin
    The German Cancer Research Center (DKFZ)
    Berlin Institute of Health (BIH))

Abstract

Intratumour heterogeneity is a major cause of treatment failure in cancer. We present in-depth analyses combining transcriptomic and genomic profiling with ultra-deep targeted sequencing of multiregional biopsies in 10 patients with neuroblastoma, a devastating childhood tumour. We observe high spatial and temporal heterogeneity in somatic mutations and somatic copy-number alterations which are reflected on the transcriptomic level. Mutations in some druggable target genes including ALK and FGFR1 are heterogeneous at diagnosis and/or relapse, raising the issue whether current target prioritization and molecular risk stratification procedures in single biopsies are sufficiently reliable for therapy decisions. The genetic heterogeneity in gene mutations and chromosome aberrations observed in deep analyses from patient courses suggest clonal evolution before treatment and under treatment pressure, and support early emergence of metastatic clones and ongoing chromosomal instability during disease evolution. We report continuous clonal evolution on mutational and copy number levels in neuroblastoma, and detail its implications for therapy selection, risk stratification and therapy resistance.

Suggested Citation

  • Karin Schmelz & Joern Toedling & Matt Huska & Maja C. Cwikla & Louisa-Marie Kruetzfeldt & Jutta Proba & Peter F. Ambros & Inge M. Ambros & Sengül Boral & Marco Lodrini & Celine Y. Chen & Martin Burker, 2021. "Spatial and temporal intratumour heterogeneity has potential consequences for single biopsy-based neuroblastoma treatment decisions," Nature Communications, Nature, vol. 12(1), pages 1-13, December.
  • Handle: RePEc:nat:natcom:v:12:y:2021:i:1:d:10.1038_s41467-021-26870-z
    DOI: 10.1038/s41467-021-26870-z
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-021-26870-z
    File Function: Abstract
    Download Restriction: no

    File URL: https://libkey.io/10.1038/s41467-021-26870-z?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Robert Vander Velde & Nara Yoon & Viktoriya Marusyk & Arda Durmaz & Andrew Dhawan & Daria Miroshnychenko & Diego Lozano-Peral & Bina Desai & Olena Balynska & Jan Poleszhuk & Liu Kenian & Mingxiang Ten, 2020. "Resistance to targeted therapies as a multifactorial, gradual adaptation to inhibitor specific selective pressures," Nature Communications, Nature, vol. 11(1), pages 1-13, December.
    2. Ricky M. Trigg & Liam C. Lee & Nina Prokoph & Leila Jahangiri & C. Patrick Reynolds & G. A. Amos Burke & Nicola A. Probst & Miaojun Han & Jamie D. Matthews & Hong Kai Lim & Eleanor Manners & Sonia Mar, 2019. "The targetable kinase PIM1 drives ALK inhibitor resistance in high-risk neuroblastoma independent of MYCN status," Nature Communications, Nature, vol. 10(1), pages 1-13, December.
    3. Isabelle Janoueix-Lerosey & Delphine Lequin & Laurence Brugières & Agnès Ribeiro & Loïc de Pontual & Valérie Combaret & Virginie Raynal & Alain Puisieux & Gudrun Schleiermacher & Gaëlle Pierron & Domi, 2008. "Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma," Nature, Nature, vol. 455(7215), pages 967-970, October.
    4. Rani E. George & Takaomi Sanda & Megan Hanna & Stefan Fröhling & William Luther II & Jianming Zhang & Yebin Ahn & Wenjun Zhou & Wendy B. London & Patrick McGrady & Liquan Xue & Sergey Zozulya & Vlad E, 2008. "Activating mutations in ALK provide a therapeutic target in neuroblastoma," Nature, Nature, vol. 455(7215), pages 975-978, October.
    5. Martin Peifer & Falk Hertwig & Frederik Roels & Daniel Dreidax & Moritz Gartlgruber & Roopika Menon & Andrea Krämer & Justin L. Roncaioli & Frederik Sand & Johannes M. Heuckmann & Fakhera Ikram & Rene, 2015. "Telomerase activation by genomic rearrangements in high-risk neuroblastoma," Nature, Nature, vol. 526(7575), pages 700-704, October.
    6. Samuel W. Brady & Yanling Liu & Xiaotu Ma & Alexander M. Gout & Kohei Hagiwara & Xin Zhou & Jian Wang & Michael Macias & Xiaolong Chen & John Easton & Heather L. Mulder & Michael Rusch & Lu Wang & Joy, 2020. "Pan-neuroblastoma analysis reveals age- and signature-associated driver alterations," Nature Communications, Nature, vol. 11(1), pages 1-13, December.
    7. Konstantin Helmsauer & Maria E. Valieva & Salaheddine Ali & Rocío Chamorro González & Robert Schöpflin & Claudia Röefzaad & Yi Bei & Heathcliff Dorado Garcia & Elias Rodriguez-Fos & Montserrat Puiggrò, 2020. "Enhancer hijacking determines extrachromosomal circular MYCN amplicon architecture in neuroblastoma," Nature Communications, Nature, vol. 11(1), pages 1-12, December.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Irfete S. Fetahu & Wolfgang Esser-Skala & Rohit Dnyansagar & Samuel Sindelar & Fikret Rifatbegovic & Andrea Bileck & Lukas Skos & Eva Bozsaky & Daria Lazic & Lisa Shaw & Marcus Tötzl & Dora Tarlungean, 2023. "Single-cell transcriptomics and epigenomics unravel the role of monocytes in neuroblastoma bone marrow metastasis," Nature Communications, Nature, vol. 14(1), pages 1-17, December.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Cécile Thirant & Agathe Peltier & Simon Durand & Amira Kramdi & Caroline Louis-Brennetot & Cécile Pierre-Eugène & Margot Gautier & Ana Costa & Amandine Grelier & Sakina Zaïdi & Nadège Gruel & Irène Ji, 2023. "Reversible transitions between noradrenergic and mesenchymal tumor identities define cell plasticity in neuroblastoma," Nature Communications, Nature, vol. 14(1), pages 1-18, December.
    2. Perla Pucci & Liam C. Lee & Miaojun Han & Jamie D. Matthews & Leila Jahangiri & Michaela Schlederer & Eleanor Manners & Annabel Sorby-Adams & Joshua Kaggie & Ricky M. Trigg & Christopher Steel & Lucy , 2024. "Targeting NRAS via miR-1304-5p or farnesyltransferase inhibition confers sensitivity to ALK inhibitors in ALK-mutant neuroblastoma," Nature Communications, Nature, vol. 15(1), pages 1-19, December.
    3. Esther R. Berko & Gabriela M. Witek & Smita Matkar & Zaritza O. Petrova & Megan A. Wu & Courtney M. Smith & Alex Daniels & Joshua Kalna & Annie Kennedy & Ivan Gostuski & Colleen Casey & Kateryna Kryts, 2023. "Circulating tumor DNA reveals mechanisms of lorlatinib resistance in patients with relapsed/refractory ALK-driven neuroblastoma," Nature Communications, Nature, vol. 14(1), pages 1-13, December.
    4. Bieke Decaesteker & Amber Louwagie & Siebe Loontiens & Fanny De Vloed & Sarah-Lee Bekaert & Juliette Roels & Suzanne Vanhauwaert & Sara De Brouwer & Ellen Sanders & Alla Berezovskaya & Geertrui Deneck, 2023. "SOX11 regulates SWI/SNF complex components as member of the adrenergic neuroblastoma core regulatory circuitry," Nature Communications, Nature, vol. 14(1), pages 1-16, December.
    5. Mark W. Youngblood & Zeynep Erson-Omay & Chang Li & Hinda Najem & Süleyman Coșkun & Evgeniya Tyrtova & Julio D. Montejo & Danielle F. Miyagishima & Tanyeri Barak & Sayoko Nishimura & Akdes Serin Harma, 2023. "Super-enhancer hijacking drives ectopic expression of hedgehog pathway ligands in meningiomas," Nature Communications, Nature, vol. 14(1), pages 1-16, December.
    6. Yanli Liu & Zhong Wu & Jin Zhou & Dinesh K. A. Ramadurai & Katelyn L. Mortenson & Estrella Aguilera-Jimenez & Yifei Yan & Xiaojun Yang & Alison M. Taylor & Katherine E. Varley & Jason Gertz & Peter S., 2021. "A predominant enhancer co-amplified with the SOX2 oncogene is necessary and sufficient for its expression in squamous cancer," Nature Communications, Nature, vol. 12(1), pages 1-14, December.
    7. Benjamin A. Nacev & Francisco Sanchez-Vega & Shaleigh A. Smith & Cristina R. Antonescu & Evan Rosenbaum & Hongyu Shi & Cerise Tang & Nicholas D. Socci & Satshil Rana & Rodrigo Gularte-Mérida & Ahmet Z, 2022. "Clinical sequencing of soft tissue and bone sarcomas delineates diverse genomic landscapes and potential therapeutic targets," Nature Communications, Nature, vol. 13(1), pages 1-15, December.
    8. Jinxin Phaedo Chen & Constantin Diekmann & Honggui Wu & Chong Chen & Giulia Chiara & Enrico Berrino & Konstantinos L. Georgiadis & Britta A. M. Bouwman & Mohit Virdi & Luuk Harbers & Sara Erika Bellom, 2024. "scCircle-seq unveils the diversity and complexity of extrachromosomal circular DNAs in single cells," Nature Communications, Nature, vol. 15(1), pages 1-14, December.
    9. Katelyn L. Mortenson & Courtney Dawes & Emily R. Wilson & Nathan E. Patchen & Hailey E. Johnson & Jason Gertz & Swneke D. Bailey & Yang Liu & Katherine E. Varley & Xiaoyang Zhang, 2024. "3D genomic analysis reveals novel enhancer-hijacking caused by complex structural alterations that drive oncogene overexpression," Nature Communications, Nature, vol. 15(1), pages 1-15, December.
    10. Fengju Chen & Yiqun Zhang & Lanlan Shen & Chad J. Creighton, 2024. "The DNA methylome of pediatric brain tumors appears shaped by structural variation and predicts survival," Nature Communications, Nature, vol. 15(1), pages 1-18, December.
    11. Irfete S. Fetahu & Wolfgang Esser-Skala & Rohit Dnyansagar & Samuel Sindelar & Fikret Rifatbegovic & Andrea Bileck & Lukas Skos & Eva Bozsaky & Daria Lazic & Lisa Shaw & Marcus Tötzl & Dora Tarlungean, 2023. "Single-cell transcriptomics and epigenomics unravel the role of monocytes in neuroblastoma bone marrow metastasis," Nature Communications, Nature, vol. 14(1), pages 1-17, December.
    12. Alexandra D’Oto & Jie Fang & Hongjian Jin & Beisi Xu & Shivendra Singh & Anoushka Mullasseril & Victoria Jones & Ahmed Abu-Zaid & Xinyu Buttlar & Bailey Cooke & Dongli Hu & Jason Shohet & Andrew J. Mu, 2021. "KDM6B promotes activation of the oncogenic CDK4/6-pRB-E2F pathway by maintaining enhancer activity in MYCN-amplified neuroblastoma," Nature Communications, Nature, vol. 12(1), pages 1-19, December.
    13. Tas ML & Van Noesel MM & Van den Boogaard ML & Schild GG & Hehir-Kwa JY & Molenaar JJ & Van Noesel MM & Van de Sande MAJ & Van de Sande MAJ & Bovée JVMG & Flucke UE & Flucke UE & Koster J, 2020. "ZFP42: A New Tumor Predisposition Gene? Presentation of a Patient with two Neoplasms in Childhood," Biomedical Journal of Scientific & Technical Research, Biomedical Research Network+, LLC, vol. 27(5), pages 21166-21172, May.
    14. Min Pan & William C. Wright & Richard H. Chapple & Asif Zubair & Manbir Sandhu & Jake E. Batchelder & Brandt C. Huddle & Jonathan Low & Kaley B. Blankenship & Yingzhe Wang & Brittney Gordon & Payton A, 2021. "The chemotherapeutic CX-5461 primarily targets TOP2B and exhibits selective activity in high-risk neuroblastoma," Nature Communications, Nature, vol. 12(1), pages 1-20, December.
    15. Steffen Fuchs & Clara Danßmann & Filippos Klironomos & Annika Winkler & Jörg Fallmann & Louisa-Marie Kruetzfeldt & Annabell Szymansky & Julian Naderi & Stephan H. Bernhart & Laura Grunewald & Konstant, 2023. "Defining the landscape of circular RNAs in neuroblastoma unveils a global suppressive function of MYCN," Nature Communications, Nature, vol. 14(1), pages 1-21, December.
    16. Ryan T. Bishop & Anna K. Miller & Matthew Froid & Niveditha Nerlakanti & Tao Li & Jeremy S. Frieling & Mostafa M. Nasr & Karl J. Nyman & Praneeth R. Sudalagunta & Rafael R. Canevarolo & Ariosto Siquei, 2024. "The bone ecosystem facilitates multiple myeloma relapse and the evolution of heterogeneous drug resistant disease," Nature Communications, Nature, vol. 15(1), pages 1-18, December.
    17. Francesc Muyas & Manuel José Gómez Rodriguez & Rita Cascão & Angela Afonso & Carolin M. Sauer & Claudia C. Faria & Isidro Cortés-Ciriano & Ignacio Flores, 2024. "The ALT pathway generates telomere fusions that can be detected in the blood of cancer patients," Nature Communications, Nature, vol. 15(1), pages 1-14, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:12:y:2021:i:1:d:10.1038_s41467-021-26870-z. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.